Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis by Inglese, M. et al.
Clinical applications of ultra-high field magnetic resonance 
imaging in multiple sclerosis
Matilde Inglese1,2,3, Lazar Fleysher2, Niels Oesingmann4, and Maria Petracca1,5
1Department of Neurology, Icahn School of Medicine, Mount Sinai, New York
2Radiology, Icahn School of Medicine, Mount Sinai, New York
3Neuroscience, Icahn School of Medicine, Mount Sinai, New York
4UK Biobank, Stockport, Cheshire, UK
5Department of Neuroscience, Federico II University, Naples, Italy
Abstract
Introduction: Magnetic resonance imaging (MRI) is of paramount importance for the early 
diagnosis of multiple sclerosis (MS) and MRI findings are part of the MS diagnostic criteria. 
There is a growing interest in the use of ultra-high-field strength −7 Tesla- (7T) MRI to 
investigate, in vivo, the pathological substrate of the disease.
Areas covered: An overview of 7T MRI applications in MS focusing on increased sensitivity 
for lesion detection, specificity of the central vein sign and better understanding of MS 
pathophysiology and discuss the implications for disease diagnosis, monitoring and treatment 
planning.
Expert commentary: 7T MRI provides increased signal-to-noise and contrast-to-noise-ratio 
that allow higher spatial resolution and better detection of anatomical and pathological features. 
The high spatial resolution reachable at 7T has been a game changer for neuroimaging 
applications not only in multiple sclerosis but also in epilepsy, brain tumors, dementia, and neuro-
psychiatric disorders. Furthermore, the first 7T device has recently been cleared for clinical use by 
the food and drug administration.
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1.0 Introduction
Multiple sclerosis (MS) is a neuroinflammatory/neurodegenerative disease of the central 
nervous system (CNS) that, according to estimates of the MS Foundation, affects more than 
two million people worldwide and represents the most common cause of non-traumatic 
disability in young adults. Although the disease etiology is still unknown, the complex 
interaction between environmental factors and the subject’s genetic background is believed 
to be play a crucial role for the disease pathogenesis. The pathological events starts with the 
priming of myelin-autoreactive T lymphocytes in the periphery that, then, cross the blood-
brain-barrier (BBB) and induce an acute autoimmune reaction against myelin and activation 
of resident microglia and infiltrated macrophages [1]. About 80–85% of patients present 
with a first acute or subacute neurological deficit lasting at least 24 hours and reflecting 
focal or multifocal CNS inflammation, that, if the MS diagnosis is subsequently confirmed 
by fulfilling dissemination in space and time (DIS and DIT respectively), is referred to as 
clinically isolated syndrome-CIS. While in the initial stage the disease manifests with 
unpredictable clinical and radiological relapses (relapsing-remitting MS-RR MS), over time 
the recurrence of relapses tends to decrease and a gradual neurological worsening occurs 
(secondary progressive MS-SP MS) [2]. In the remaining 20–15% of cases, the disease is 
characterized by a gradual clinical worsening over time independent of relapses (primary 
progressive MS-PP MS) [1].
Magnetic resonance imaging (MRI) is of paramount importance for the early MS diagnosis 
and MRI parameters are part of the MS diagnostic criteria. MS diagnosis in patients with 
symptoms consistent with a CNS inflammatory demyelinating disease is based on the 
presence of clinical and MRI criteria of DIS and DIT, coupled with the exclusion of 
alternative diagnoses that could offer a better explanation for the patient’s clinical 
presentation [3]. Furthermore, MRI is of crucial importance for monitoring treatment 
response in clinical practice and experimental trials and for investigating the disease 
pathophysiology.
There is a growing interest in the use of MRI at ultra-high-field strength −7 Tesla- (7T) to 
investigate disease mechanisms in patients with MS. The main advantages of 7T MRI are 
the increased signal-to-noise ratio (SNR) and the contrast-to-noise-ratio (CNR) that allow 
the improvement of spatial resolution and the detection of anatomical and pathological 
features. Three major MR vendors currently provide 7 T MRI magnets for ethically 
approved clinical research. The number of installations in operation has increased to over 70 
during the last several years. More recently, the food and drug administration (FDA) cleared 
the first 7T device (Magnetom Terra, Siemens Medical Solutions Inc.) for clinical use 
limited to the examination of head and extremities [4].
In this review we will present the main findings obtained by the application of 7T MRI in 
patients with MS in terms of increased detection of white and gray matter lesions, and 
potential increased specificity of the “central vein sign”. Then, we will discuss the 
implications of these findings for disease diagnosis, monitoring and treatment planning. 
Finally, we will review the relevance of 7T MRI applications for a better understanding of 
MS pathophysiology and elucidation of the underlying mechanisms.
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2.0 Multiple Sclerosis diagnosis
MS diagnosis is based on the demonstration of lesion dissemination in space and time (DIS 
and DIT respectively), coupled with the exclusion of alternative diagnoses, in patients who 
present with a typical clinically isolated syndrome (CIS) suggestive of MS or symptoms 
consistent with a CNS inflammatory demyelinating disease [3].
Typical presentations include unilateral optic neuritis, focal supratentorial syndrome, focal 
brainstem or cerebellar syndrome, or partial myelopathy. In patients presenting CIS, a 
diagnosis of MS purely based on clinical symptom is theoretically possible when a second 
relapse occurs, in presence of objective clinical evidence of two lesions, when there is 
objective clinical evidence of one lesion with reasonable historical evidence of a prior attack, 
or if it is possible to demonstrate CSF-specific oligoclonal bands but access to imaging is 
always desirable to confirm DIS and DIT and, in particular, to exclude alternative diagnosis.
Radiological DIS is defined as one or more T2 hyperintense lesions within at least two of 
four anatomical locations characteristic for MS (periventricular, cortical or juxtacortical, 
infratentorial, spinal cord).
Radiological DIT is demonstrated by the presence of (i) gadolinium-enhancing and non-
enhancing lesions on the same MRI or (ii) new T2 hyperintense and/or gadolinium-
enhancing lesions on follow-up MRI compared to baseline, regardless of the time interval 
between the two scans.
Both symptomatic and asymptomatic MRI lesions can be considered to define DIS and DIT.
Cerebral spinal fluid (CSF) analysis can be used in support of the diagnosis of primary 
progressive MS that requires, in addition to one year of disease progression, two of the 
following criteria: (i) brain DIS based on at least one T2 lesion in at least one area 
characteristic for MS (periventricular, cortical or juxtacortical, infratentorial) (ii) spinal cord 
DIS based on at least two T2 lesions (iii) evidence of oligoclonal bands and/or elevated IgG 
index in the CSF.
In order to facilitate the application of these criteria in clinical settings, guidelines for the 
standardization of MR protocols utilized in MS diagnosis and follow-up have been 
published [5,6].
While the recent 2017 revision to McDonald criteria does not address directly the role of 
high field strength imaging in MS diagnosis, it identifies the issue as a high-priority area for 
research. Additionally, last year, the MAGNIMS study group concluded, in their consensus 
guidelines, that, although the current evidence does not support yet the application of 7T 
MRI scanners for an earlier diagnosis of MS, the increased sensitivity in lesion detection and 
the better characterization of lesion pathology at high- and ultra-high field MRI could lead to 
higher specificity, enhancing differentiation of MS from other disorders [7].
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3.0 Advantages and challenges of 7 Tesla MRI
Since SNR scales with the field, 7T MRI provides images with higher spatial resolution 
within reasonable acquisition times and with finer anatomical details (Figure 1). In addition, 
7T allows increased detection of subtle brain abnormalities that may improve disease 
diagnosis. The effects of small variations in tissue susceptibility are increased at ultra-high 
field MR leading to greater changes in image contrast especially in proximity of tissue with 
high density of small venous structures and high iron deposits [8]. Therefore, the combined 
effect of increased spatial resolution and susceptibility-based contrast has enabled the study 
of venous vasculature and the assessment of its relationship with perivenular infiltrates and 
inflammation in MS lesions [9].
The gain in SNR and CNR, however, occurs at the expense of increased radiofrequency (B1) 
and static field (B0) inhomogeneity, which result in a variation of intensity across the image 
and distortions at structural boundaries that, in turn, can limit the interpretation of findings 
[10]. The direct scaling of B0 inhomogeneity with field strength results in distortions of 
image geometry and intensity especially in rapid acquisition schemes such as echo-planar 
imaging that are more prone to distortions due to susceptibility effects. With the increase of 
B0 field at 7T, B1 strength decreases in the brain periphery compared with the center 
resulting in signal drop-out and changes in image contrast. Nonetheless, the ongoing 
technical development of customized RF pulse and pulse sequence designs as well as the 
development of multiple transmit coils for RF signal transmission will help overcome the 
physical limitations of performing 7T imaging in vivo within recommended safety limits and 
reasonable acquisition times.
Furthermore, although risks at 7T are similar to those at lower field strength, there are 
additional concerns related to patients’ safety. Noise levels, RF energy deposition, and 
peripheral nerve stimulation are minimized by the adherence to the FDA safety guidelines. 
The limited numbers of implantable devices tested so far at 7T can limit the target 
population. However, several implants are currently under testing and will allow 7T imaging 
in a wider number of patients [11].
3.1 White matter lesions detection
The initial 7T MRI studies of patients with MS focused on investigating the relationship 
between WM lesions and small parenchymal blood vessels using susceptibility sensitive 
imaging [12,13]. The presence of a close relationship between demyelination and blood 
vessels had already been reported at post-mortem examination of MS samples [14,15] and 
T2-weighted MR images at 1.5T with subsequent venography had previously demonstrated 
an MS lesion and a blood vessel in close proximity [16]. However, only the application of 
7T T2*-weighted MRI was able to demonstrate both structures simultaneously [12,13]. 
Periventricular lesions were defined as those with a border within 4 mm of the ventricular 
surface while all other lesions were defined as peripheral. Vessels appeared hypointense and 
were only counted if they could be visualized in at least two perpendicular planes. In line 
with histologic reports, a central vessel could be identified in 73 lesions (82%) in 8 MS 
patients supporting the good sensitivity of the technique[13]. Periventricular lesions were 
more likely to display a central vessel than peripheral lesions due, potentially, to a different 
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mechanism of lesion development depending on localization or due to the general smaller 
size of peripheral lesions and the higher likelihood for them to be associated with smaller 
vessels.
These first 7T T2*-weighted MRI studies raised questions about the potential higher 
sensitivity of 7T MRI for detection of WM lesions compared to lower field MRI, about the 
clinical implication of an early MS diagnosis and about the potential high specificity of the 
“central vein sign” in the differential diagnosis of MS and other diseases mimicking MS.
In terms of higher sensitivity, the first comparative study between WM lesion detection at 7T 
versus 1.5T [17] did not show the expected gain due to the high specific absorption rate of 
radiofrequency energy that makes difficult to implement some of the clinical sequences at 
ultra-high field.
While the optimization of inversion recovery spin echo sequences such as FLAIR remains 
challenging at 7T, 3D MPRAGE is less affected by RF inhomogeneity, and therefore, one of 
the first comparative study between lesion detection at 7T and 3T focused on the comparison 
of standard clinical 3T FLAIR and MPRAGE sequences with 7T MPRAGE [18]. Although 
the majority of lesions were detected on both FLAIR and MPRAGE images, a substantial 
proportion were only detected using 3T MPRAGE (19% of the total number of lesions 
detected) and 7T MPRAGE (22% of the total number of lesions detected). Moreover, 
significantly more lesions were detected using 7T MPRAGE compared with 3T MPRAGE 
(p=0.012). 7T SNR resulted suboptimal in the lower half of the brain thus explaining why 
some lesions were missed on 7T MPRAGE compared with 3T FLAIR/MPRAGE. 
Admittedly, this improved lesion detection was limited by the presence of 3T FLAIR lesions 
not seen on 7T, mostly in the infra-tentorium, where there was signal dropout at 7T. There is 
encouraging evidence, however, that this issue might be resolved through the use of the 
advanced magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE) 
technique, which corrects the image intensity variations due to large spatial B1 field 
inhomogeneities and thus can provide homogeneous T1 contrast across the entire brain at 7T 
[19]. Importantly, many of the lesions only detected on 7T were within what would have 
been interpreted as normal-appearing WM at 3T, supporting the notion that focal MS lesions 
contribute to the abnormalities known to exist in the normal-appearing WM.
3.2 White matter lesions and the “central vein sign”
Although the diagnosis of MS is based on the identification of multifocal demyelinating 
lesions, which are disseminated in their time of onset, focal T2 lesions are not specific to 
MS, occurring in several other neurological disorders [20]. The finding that a central vessel 
could be identified in 45% of visible lesions using 3T T2* and 87% of visible lesions using 
7T T2* (P = 0.0001) in MS patients [21] and in only 8% of the discrete WM lesions of 
healthy volunteers prompted further investigation as this would represent a clinically useful 
application.
Based on the demonstration that at T2* weighted imaging at 7T most MS lesions are 
centered on small parenchymal veins, Tallantyre et al. compared the appearance of brain 
lesions between patients with MS and patients with asymptomatic WM lesions to assess 
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whether the central vein sign has a diagnostic value and differentiates between MS lesions 
and microangiopathic lesions [9]. WM lesions were identified on 7T T2* weighted MRI 
from 28 MS patients and 17 patients with cerebral WM lesions who did not have MS and 
analyzed for volume, location, and perivenous appearance. In MS patients, 80% of the 901 
identified lesions were perivenous, while in non-MS patients only 19% of 428 identified 
lesions were perivenous. In addition, 7T T2*-weighted MRI reliably distinguished all 
patients with clinically definite MS (>40% lesions appeared perivenous) from those without 
clinical MS (<40% lesions appeared perivenous). Finally, perivenous lesion appearance was 
more predictive of MS (p <0.001) than subcortical or periventricular lesion location.
Over the past few years, various research groups have used 3T and 7T T2*-weighted MRI to 
evaluate the presence of central veins inside WM lesions associated with various 
neurological diseases, including neuromyelitis optica spectrum disorder (NMOSD), 
systemic autoimmune diseases (SAD), cerebral small vessel disease (CSVD), Susac 
syndrome, and migraine supporting the concept that the central vein sign may contribute to 
the differential diagnosis (Figure 2) [22].
Therefore, the central vein sign (CVS) has recently been proposed as a novel MRI biomarker 
to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of 
the CVS in individual lesions can accurately differentiate MS from other diseases that mimic 
this condition.
However, further studies are needed to establish the predictive value of the CVS for the 
development of clinical MS in patients with suspected demyelinating disease. Guidelines for 
the assessment of the CVS are nicely outlined in an expert consensus document recently 
published by the North American imaging in MS Cooperative [22]. As highlighted in this 
consensus statement, although T2* imaging is most sensitive at 7T, a high detection rate can 
still be achieved at clinical field strengths (1.5T and 3T) when applying optimized 
sequences.
3.3 Cortical and subcortical gray matter lesion detection
The increased spatial resolution and better tissue contrast of 7T imaging has been of crucial 
importance for the detection of cortical and subcortical GM lesions [17,23–30]. Cortical 
lesions are very frequent at histopathological examination, especially in the progressive 
forms of the disease [31]; however, due to the small size and lower amount of inflammation 
it is very difficult to detect them with in vivo MRI. Since the first ex-vivo and in vivo 
applications, it was clear that 7T MRI (e.g. T2*-weighted gradient echo and MPRAGE) 
improves not only detection of cortical lesions compared to 3T MRI but it also improves 
lesions localization and classification (Figure 3) [24]. To date, most of the 7T MRI study 
have used and compared several sequences with controversial results explained by the fact 
that each sequence has advantages and limitations and there is ongoing effort towards their 
optimization. For instance, one study evaluated the agreement between FLAIR, DIR and 
MPRAGE in 11 MS patients and 8 healthy controls that underwent FLAIR and DIR at 3T 
and MPRAGE at 7T [26]. While the agreement for cortical lesions was good between 
images, the agreement for intracortical lesions was less satisfactory and 25% of lesions 
could only be visualized on a single MRI sequence. Each sequence gave a complementary 
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contribution to lesion detection with 7T MPRAGE facilitating the localization of lesions at 
the cortical boundary. A recent post-mortem study [32] comparing T2-, T1-, T2*-weighted 
sequences, FLAIR and DIR at 3T and 7T showed that none of the five sequences detected 
significant more lesions than any other sequence and that subpial cortical lesions were more 
extensive than what is revealed by the 7T. Continuous optimization of MRI sequences and 
coil technology at 7T is likely to lead to a better detection and classification of gray matter 
whose recognized clinical relevance could benefit MS patients’ management and treatment.
3.4 Small CNS anatomical regions
The increased SNR and higher spatial resolution of 7T imaging could be also beneficial to 
the study of small anatomical regions of the central nervous system and the related 
pathological abnormalities (Figure 4).
For instance, imaging of the spinal cord has always been challenging at lower MR field 
strengths due to the small size, surrounding bone-tissue interfaces and artifacts associated to 
respiratory- and cardiac-induced artifacts that limit the assessment of demyelinating lesions. 
A small comparative study of spinal cord imaging of MS patients at 3T and 7T has shown 
that not only 7T provides a better visualization of fine anatomical details such as the nerve 
roots and a better demarcation of gray and white matter, but it also improves by 50% spinal 
cord MS lesion detection [33]. Although there is a need for further technical development, 
these results are very promising and may be of great relevance since the spinal cord 
involvement accounts for most of patients’ clinical disability.
3.5 Quantitative imaging
3.5.1 Iron imaging—T2*-weighted gradient-echo sequence and susceptibility weighted 
imaging have proved useful not only for the visualization of the central vein but also for the 
quantification of iron deposits. After the finding that approximately 8% of MS lesions 
detected at 7T with gradient echo sequence show a rim on phase image [34], radiological-
histopathological correlation studies have demonstrated the presence of iron within 
phagocytic macrophages and/or microglia in phase-rim MS lesions, providing a histologic 
validation for the radiological finding [35,36]. It has also been suggested that chronic phase-
rim lesions are characterized by greater tissue destruction compared with non–phase-rim 
lesions, and therefore their identification and their evolution might be relevant for the 
understanding of disease progression and for patients’ treatment plans.
Although it is important to bear in mind that iron-sensitive sequences are also sensitive to 
changes in tissue density, water and fiber orientation, recent studies have applied an 
alternative technique to process gradient echo data, namely quantitative susceptibility 
mapping (QSM), that, by removing some of the contributors that complicate the 
interpretation of phase images, seems to improve our insights on the changes occurring at 
the periphery of MS lesions [37,38].
3.5.2 Multinuclear imaging—The greater SNR at 7T provides a signal boost to nuclei 
such as sodium (23Na) and phosphorus (31P) whose brain concentration is much lower than 
that of proton nuclei. In this review we will focus on sodium imaging since there are a few 
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studies that have investigated brain sodium concentration in patients with MS. For more 
details about multinuclear imaging at ultra-high field MRI see Balchandani et al [39].
When demyelination occurs in MS, 23Na channels present a widespread re-distribution from 
the Ranvier nodes to long segments of demyelinated membrane. While this represents an 
adaptive mechanism to preserve action potential conduction and facilitate recovery of 
neurological deficits, it imposes a huge burden on the axonal metabolism thus increasing the 
risk of axonal damage secondary to energy deprivation [40,41]. In MS, however, in presence 
of mitochondrial dysfunction and ATP deficit, 23Na influx leads to the axonal accumulation 
of toxic levels of calcium [42,43] and neurodegeneration. Interestingly, it has been shown 
that 23Na channels blockers are able to protect axons from anoxic-ischemic injury in vitro 
[43–47] and in animal models of MS [48–52], at concentrations that do not compromise the 
conduction of action potentials.
23Na yields the second strongest nuclear magnetic resonance (NMR) signal among 
biologically relevant NMR-active nuclei. 23Na concentration is strictly controlled by the 
ATP-driven Na/K pump to ensure the maintenance of tissue homeostasis and the 
preservation of intracellular structures and processes. Therefore, pathological changes such 
as tissue injury, edema or necrosis or functional impairment of the Na/K pump are expected 
to result in an increased tissue 23Na concentration [53–56].
Single quantum (SQ) 23Na MRI is an imaging technique that exploits the magnetic 
resonance properties of 23Na atomic nuclei, allowing the metabolic characterization of brain 
tissue in vivo. Unfortunately, the sodium signal is 30,000 times lower than that of protons 
due to the low brain concentration, smaller gyromagnetic ration and rapid bio-exponential 
decay [57]. Moreover, in the brain 23Na has a bi-compartimental distribution with higher 
concentration (140 mmol/L) in the extracellular space and a lower concentration (ranging 
from 10 to 15 mmol/L) in the intracellular space. All these features of sodium signal make 
high- and ultra-high field magnets highly desirable to improve sensitivity of in vivo 23Na 
MRI.
Several 3T sodium MRI studies from different laboratories around the world [58–64] have 
showed a widespread brain increase of total tissue sodium concentration (TSC) in patients 
with MS suggesting that this might reflect changes in cellular and metabolic integrity of 
both lesions and normal-appearing brain tissue. While in the early disease stage TSC 
increase is prevalent in macroscopic lesions [60], it spreads to normal-appearing white 
matter, cortical and deep gray matter as the disease progresses [58–61]. TSC increase in 
lesions might be explained by gliosis, tissue disruption and replacement with extracellular 
fluid, whereas TSC increase in normal-appearing brain tissue is related not only to increased 
extracellular space, caused by demyelination and axonal loss, but also to intra-axonal 23Na 
increase.
Although TSC can help monitoring the occurrence of tissue injury and disability, it is not 
useful in discriminating metabolic dysfunction from the irreversible cellular damage. 
Metabolic changes that affect 23Na exchange across cells membrane influence the 
intracellular sodium concentration (ISC) [53], that could therefore be considered as a pure 
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functional marker. More recently, we have combined SQ and triple-quantum filtered 23Na 
MRI at 7T [65,66] and applied this technique to a small number of MS patients to quantify 
ISC and intracellular 23Na volume fraction, an indirect measure of extracellular 23Na 
concentration [67] (Figure 5). Our preliminary findings suggest that the ISC increase 
detected in the brain WM of patients compared to healthy controls might indicate axonal 
dysfunction, offering insights in axonal metabolism before the generation of stable, 
irreversible, axonal damage. Since the ISC accumulation is a reversible phenomenon, 
occurring spontaneously in a number of neurons in physiological conditions [68], it could be 
a putative target for therapeutic interventions.
4.0 Conclusion
7T MRI has improved the ability to detect ever smaller brain lesions, in both WM and GM, 
and to improve their localization in MS. Further technical implementation is needed to 
overcome the current limitations, especially in detection of cortical lesions. The “central 
vein sign” (CVS) might serve as a novel MRI biomarker to improve the accuracy and speed 
of MS diagnosis. However, further studies are needed to establish the predictive value of the 
CVS for the development of clinical MS in patient with suspected demyelinating disease. 
Metabolic and functional imaging as well as imaging of nuclei other than protons are ready 
for applications and can provide unique information to elucidate the mechanisms underlying 
the disease. Continued technical development of new signal transmission and readout 
methods is needed to overcome the limitations of performing 7T MRI within comfortable 
times and accepted safety limits. Additional clinical studies are needed to demonstrate the 
value of 7T for disease diagnosis, prognosis, treatment, and management.
5.0 Expert Commentary
Offering a substantial increase in signal-to-noise ratio (SNR) and the contrast-to-noise-ratio 
(CNR) 7T imaging grants an anatomical definition not achievable with lower field strength, 
thus providing a fundamental tool for the exploration, in vivo, of physiological mechanisms 
and pathological substrate of a variety of neurological disorders. The key finding of the 
research done in this field so far is the successful overcoming of many technical challenges 
for structural and functional 7T imaging enabling the visualization of cortical layers and fine 
structure of small nuclei in the human brain with unprecedented detail. The high spatial 
resolution reachable at 7T has been a game changer for neuroimaging applications not only 
in multiple sclerosis but also in epilepsy, brain tumors, dementia, and neuro-psychiatric 
disorders. Specifically, in MS the higher white matter lesion detection provided by 7T and 
the potential higher specificity provided by the central vein sign in white matter lesions 
could significantly impact the diagnosis and the differential diagnosis of MS.
Additional clinical studies are needed to demonstrate the value of 7T for disease diagnosis, 
treatment, and management. This goal can be achieved with the larger availability of 7T 
scanners allowing for multi-site studies and with lowering the cost of such magnets. The 
recent FDA clearance of the first 7T device (Magnetom Terra, Siemens Medical Solutions 
Inc.) for clinical use will boost the production of 7T scanners that will be available in an 
increasing number of research and clinical Institution thus reducing the unit cost. Moreover, 
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since most of the newer scanner are “zero boil-off” there is very little helium leak with time 
further reducing helium cost after the initial magnet installation. Therefore, clinical 7T 
applications, especially in neurological and musculoskeletal MRI applications, are expected 
to full bloom in the near future.
Besides clinical applications, 7T holds a huge potential for research applications made 
possible by the related improvement in several imaging modalities. Vascular and functional 
imaging takes advantage of the increased susceptibility at ultra-high field and enables a more 
effective visualization of smaller blood vessels, microbleeds and iron deposits through 
susceptibility weighted imaging and angiography. Magnetic resonance spectroscopy is 
benefited not only by the increased SNR but also by the increased spectral resolution that 
improves the quantification of the most commons metabolites and allows the visualization of 
low concentration metabolites not detectable at lower MR field strength. Another interesting 
field of research made possible by 7T is that of multinuclear MRI characterized by the 
imaging of nuclei other than protons (sodium-23, phosphorus-31, and chlorine-35) whose 
signals is much lower than the signal from protons and, therefore is boosted at 7T MRI and 
provides important information about cellular processes and ion homeostasis.
Several technical challenges and a few patients’ concerns remain, however, to be addressed. 
The major issues are represented by the inhomogeneity of B0 and B1 fields with consequent 
image artifacts and limited brain spatial coverage and by the increased deposition of RF 
power within subjects. Therefore, it is necessary to find technical solutions to overcome the 
physical challenges of 7T imaging and improve the safety issues. Indeed, brain imaging at 
7T is booming with rapid developments in customized RF pulse, pulse sequence design, 
reconstruction techniques, improved gradient performance and specialized hardware such as 
new multiple transmit coils for RF signal transmission.
This continued innovative research in terms of technical development of new hardware, 
pulse sequences and readout methods will further mitigate the challenges of 7T thus 
enabling imaging within clinically reasonable times and in respect of safety limits.
6.0 Five-year view
With the FDA clearance of the first 7T device for clinical use in the brain and with the ever- 
increasing number of 7T magnets installed worldwide we expect a growing application of 
this method in neurological diseases. Continued technical implementation and optimization 
will allow to overcome present limitations and will move forward clinical applications. 
Future effort will focus on the performance of larger clinical studies to demonstrate the 
value of 7T for MS diagnosis, prognosis, treatment, and management of MS. Similarly, the 
access to finer anatomical and pathological details and the opportunity to study disease 
mechanisms of cortical layers demyelination, lesion development and evolution, meningeal 
inflammation, iron deposits and sodium dyshomeostasis will enable us to make the next 
steps forward in understanding MS pathophysiology and will provide better tools to 
investigate the effects of physical and pharmacological therapies.
Inglese et al. Page 10
Expert Rev Neurother. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
Funding
This study was supported in part by grants from National Institute of Health (R01NS099527), Teva Neuroscience 
(CNS-2014–221), and the Noto Foundation.
References
Papers of special note have been highlighted as:
* of interest
** of considerable interest
[1]. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517. [PubMed: 18970977] 
[2]. Lublin FD, Reingold SC, Cohen J a, et al. Defining the clinical course of multiple sclerosis: The 
2013 revisions. Neurology. 2014;83:1–9.
[3]. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the 
McDonald criteria. Lancet Neurol. 2017 pii: S1474–4422(17)30470–2.* Current criteria for 
multiple sclerosis diagnosis
[4]. Voelker R Twice the Power in New MRI. JAMA. 2017;318:2017.** First report of FDA clearance 
for 7T clinical use
[5]. Traboulsee a L, Simon J, Stone L, et al. Revised Recommendations of the Consortium of MS 
Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis 
and Follow-Up of Multiple Sclerosis. AJNR. Am. J. Neuroradiol. 2016;314:2034–2044.
[6]. Rovira Á, Wattjes MP, Tintoré M, et al. Evidence-based guidelines: MAGNIMS consensus 
guidelines on the use of MRI in multiple sclerosis - Clinical implementation in the diagnostic 
process. Nat. Rev. Neurol. 2015;11:471–482. [PubMed: 26149978] 
[7]. Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: 
MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303. [PubMed: 26822746] 
[8]. Duyn JH. The future of ultra-high field MRI and fMRI for study of the human brain. Neuroimage. 
2012;62:1241–1248. [PubMed: 22063093] 
[9]. Tallantyre EC, Dixon JE, Donaldson I, et al. Ultra-high-field imaging distinguishes MS lesions 
from asymptomatic white matter lesions. Neurology. 2011;76:534–539. [PubMed: 21300968] * 
Pathological specificity of perivenous lesion location
[10]. Uǧurbil K, Adriany G, Andersen P, et al. Ultrahigh field magnetic resonance imaging and 
spectroscopy. Magn. Reson. Imaging. 2003;21:1263–1281. [PubMed: 14725934] 
[11]. Trattnig S, Springer E, Bogner W, et al. Key clinical benefits of neuroimaging at 7T. Neuroimage. 
2016;S1053–8119:30651–30656.
[12]. Ge Y, Zohrabian VM, Grossman RI. Seven-Tesla Magnetic Resonance Imaging. JAMA Neurol. 
2009;65:812–816.
[13]. Tallantyre EC, Brookes M, Dixon J, et al. Demonstrating the perivascular distribution of MS 
lesions in vivo with 7-Tesla MRI. Neurology. 2008;70:2076–2078. [PubMed: 18505982] 
[14]. Fog T On the vessel-plaque relationships in the brain in multiple sclerosis. Acta Neurol Scand. 
1964;40:9–15.
[15]. Adams C, Poston R, Bulk S. Pathology, histochemistry and immunocytochemistry of lesions in 
acute multiple sclerosis. J Neurol Sci. 1989;92:291–306. [PubMed: 2809622] 
[16]. Tan IL, Van Schijndel RA, Pouwels PJW, et al. MR venography of multiple sclerosis. Am. J. 
Neuroradiol. 2000;21:1039–1042. [PubMed: 10871010] 
[17]. Kollia K, Maderwald S, Putzki N, et al. First clinical study on ultra-high-field MR imaging in 
patients with multiple sclerosis: Comparison of 1.5T and 7T. Am. J. Neuroradiol. 2009;30:699–
702. [PubMed: 19147714] ** Direct comparison of 1.5 and 7T imaging
Inglese et al. Page 11
Expert Rev Neurother. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[18]. Mistry N, Tallantyre EC, Dixon JE, et al. Focal multiple sclerosis lesions abound in “normal 
appearing white matter.” Mult. Scler. J. 2011;17:1313–1323.
[19]. Marques JP, Kober T, Krueger G, et al. MP2RAGE, a self bias-field corrected sequence for 
improved segmentation and T1-mapping at high field. Neuroimage. 2010;49:1271–1281. 
[PubMed: 19819338] 
[20]. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 
revisions to the McDonald criteria. Ann. Neurol. 2011;69:292–302. [PubMed: 21387374] 
[21]. Tallantyre EC, Morgan PS, Dixon JE, et al. A Comparison of 3T and 7T in the Detection of 
Small Parenchymal Veins Within MS Lesions. Invest. Radiol. 2009;44:491–494. [PubMed: 
19652606] 
[22]. Sati P, Oh J, Todd Constable R, et al. The central vein sign and its clinical evaluation for the 
diagnosis of multiple sclerosis: A consensus statement from the North American Imaging in 
Multiple Sclerosis Cooperative. Nat. Rev. Neurol. 2016;12:714–722. [PubMed: 27834394] ** 
The role of the central vein sign in the diagnosis of multiple sclerosis
[23]. Kangarlu A, Bourekas EC, Ray-Chaudhury a, et al. Cerebral cortical lesions in multiple sclerosis 
detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol. 2007 2;28(2):262–6. [PubMed: 
17296991] 
[24]. Mainero C, Radding A. In vivo imaging of cortical pathology in multiple sclerosis using ultra-
high field MRI. Neurology. 2009;941–948. [PubMed: 19641168] ** Utility of 7T for in vivo 
classification of corticol lesions
[25]. Metcalf M, Xu D, Okuda DT, et al. High-resolution phased-array MRI of the human brain at 7 
tesla: Initial experience in multiple sclerosis patients. J. Neuroimaging. 2010;20:141–147. 
[PubMed: 19187478] 
[26]. Tallantyre EC, Morgan PS, Dixon JE, et al. 3 Tesla and 7 Tesla MRI of multiple sclerosis cortical 
lesions. J. Magn. Reson. Imaging. 2010;32:971–977. [PubMed: 20882628] 
[27]. Pitt D, Boster A, Pei W, et al. Imaging Cortical Lesions in Multiple Sclerosis With Ultra–High-
Field Magnetic Resonance Imaging. JAMA Neurol. 2015;67:812–818.
[28]. Nielsen AS, Kinkel RP, Tinelli E, et al. Focal cortical lesion detection in multiple sclerosis: 3 
tesla DIR versus 7 tesla FLASH-T2. J. Magn. Reson. Imaging. 2012;35:537–542. [PubMed: 
22045554] 
[29]. Yao B, Hametner S, Van Gelderen P, et al. 7 Tesla magnetic resonance imaging to detect cortical 
pathology in multiple sclerosis. PLoS One. 2014;9:e108863. [PubMed: 25303286] 
[30]. Harrison DM, Oh J, Roy S, et al. Thalamic lesions in multiple sclerosis by 7T MRI: clinical 
implications nad relationship to cortical pathology. Mult. Scler. 2015;21:1139–1150. [PubMed: 
25583851] 
[31]. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white 
matter injury in multiple sclerosis. Brain. 2005;128:2705–2712. [PubMed: 16230320] 
[32]. Kilsdonk ID, Jonkman LE, Klaver R, et al. Increased cortical grey matter lesion detection in 
multiple sclerosis with 7 T MRI: A post-mortem verification study. Brain. 2016;139:1472–1481. 
[PubMed: 26956422] 
[33]. Dula AN, Pawate S, Dortch RD, et al. Magnetic Resonance Imaging of the Cervical Spinal Cord 
in Multiple Sclerosis at 7T. Mult. Scler. 2017;22:320–328.** 7T application to the study of small 
structures
[34]. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of 
multiple sclerosis at 7 Tesla with sensitivity to iron. Ann. Neurol. 2008;64:707–713. [PubMed: 
19107998] 
[35]. Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: A combined imaging 
and histopathological study at 7 Tesla. Brain. 2011;134:3599–3612.** Combined imaging and 
pathological study demonstrating 7T sensitivity to iron identification
[36]. Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts poor outcome in new 
multiple sclerosis patient lesions. J. Clin. Invest. 2016;126:2597–2609. [PubMed: 27270171] 
[37]. Cronin MJ, Wharton S, Al-Radaideh A, et al. A comparison of phase imaging and quantitative 
susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field. Magn. 
Reson. Mater. Physics, Biol. Med. 2016;29:543–557.
Inglese et al. Page 12
Expert Rev Neurother. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[38]. Wang Y, Spincemaille P, Liu Z, et al. Clinical quantitative susceptibility mapping (QSM): 
Biometal imaging and its emerging roles in patient care. J. Magn. Reson. Imaging. 2017;46:951–
971. [PubMed: 28295954] 
[39]. Balchandani P, Naidich TP. Ultra-high-field MR neuroimaging. Am. J. Neuroradiol. 
2015;36:1204–1215. [PubMed: 25523591] 
[40]. Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis : 
Altered axonal expression of Na v 1 . 2 and Na v 1 . 6 sodium channels and Na+/Ca2+ 
exchanger. PNAS. 2004;101:8168–8173. [PubMed: 15148385] 
[41]. England JD, Gamboni F, Levinson SR. Increased numbers of sodium channels form along 
demyelinated axons. 1991;548:334–337.
[42]. Waxman SG. Conduction in Myelinated, Unmyelinated, and Demyelinated Fibers. Arch. Neurol. 
1977;34:585–589. [PubMed: 907529] 
[43]. Stys PK, Lesiuk H. Correlation between electrophysiological effects of mexiletine and ischemic 
protection in central nervous system white matter. Neuroscience. 1996;71:27–36. [PubMed: 
8834390] 
[44]. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS 
white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J. Neurosci. 1992;12:430–439. 
[PubMed: 1311030] 
[45]. Stys K, Ransom R, Waxman G. Tertiary and Quatemary Local Anesthetics Protect CNS White 
Matter From Anoxic Injury at Concentrations That do not Block Excitability. 1992;67:1–5.
[46]. Fern R, Ransom BR, Stys PK, et al. Pharmacological protection of CNS white matter during 
anoxia: actions of phenytoin, carbamazepine and diazepam. J. Pharmacol. Exp. Ther. 
1993;266:1549–1555. [PubMed: 8371157] 
[47]. Stys PK. Protective Effects of Antiarrhythmic Agents Against Anoxic Injury in eNS White 
Matter. J. Cereb. blood flow Metab. 1995;15:425–432. [PubMed: 7714000] 
[48]. Bechtold D a, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental 
autoimmune encephalomyelitis. Ann. Neurol. 2004;55:607–616. [PubMed: 15122700] 
[49]. Lo AC, Saab CY, Black J a, et al. Phenytoin protects spinal cord axons and preserves axonal 
conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol. 
2003;90:3566–3571. [PubMed: 12904334] 
[50]. Black J a, Liu S, Carrithers M, et al. Exacerbation of experimental autoimmune 
encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 2007;62:21–
33. [PubMed: 17654737] 
[51]. Bechtold D a, Miller SJ, Dawson AC, et al. Axonal protection achieved in a model of multiple 
sclerosis using lamotrigine. J. Neurol. 2006;253:1542–1551. [PubMed: 17219031] 
[52]. Al-Izki S, Pryce G, Hankey DJR, et al. Lesional-targeting of neuroprotection to the inflammatory 
penumbra in experimental multiple sclerosis. Brain. 2014;137:92–108. [PubMed: 24287115] 
[53]. Jain RK. Transport of Molecules in the Tumor Interstitium : A Review Transport of. Cancer Res. 
1987;47:3039–3051. [PubMed: 3555767] 
[54]. Camero IL, Smith NKR, Pool TB, et al. Intracellular Concentration of Sodium and Other 
Elements as Related to Mitogenesis and Oncogenesis in Vivo. Cancer Res. 1980;40:1493–1500. 
[PubMed: 7370987] 
[55]. Nagy IZ, Lustyik G, Lukács G, et al. Correlation of Malignancy with the Intracellular Na + : K + 
Ratio in Human Thyroid Tumors. Cancer Res. 1983;43:5395–5402. [PubMed: 6616471] 
[56]. Thulborn KR, Davis D, Snyder J, et al. Sodium MR Imaging of Acute and Subacute Stroke for 
Assessment of Tissue Viability. Neuroimaging Clin. N. Am. 2005;15:639–653. [PubMed: 
16360594] 
[57]. Maudsley AA, Hilal SK. Biological aspects of sodium-23 imaging. Br. Med. Bull. 1984;40:165–
166. [PubMed: 6744003] 
[58]. Inglese M, Madelin G, Oesingmann N, et al. Brain tissue sodium concentration in multiple 
sclerosis: a sodium imaging study at 3 tesla. Brain. 2010;133:847–857. [PubMed: 20110245] 
[59]. Paling D, Solanky BS, Riemer F, et al. Sodium accumulation is associated with disability and a 
progressive course in multiple sclerosis. Brain. 2013;136:2305–2317. [PubMed: 23801742] 
Inglese et al. Page 13
Expert Rev Neurother. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[60]. Zaaraoui W, Konstandin S, Audoin B, et al. Distribution of Brain Sodium Accumulation 
Correlates with Disability in Multiple Sclerosis : Radiology. 2012;264:859–867. [PubMed: 
22807483] 
[61]. Maarouf A, Audoin B, Konstandin S, et al. Topography of brain sodium accumulation in 
progressive multiple sclerosis. MAGMA. 2014;27:53–62. [PubMed: 23907269] 
[62]. Maarouf A, Audoin B, Pariollaud F, et al. Increased total sodium concentration in gray matter 
better explains cognition than atrophy in MS. Neurology. 2017;88:289–295. [PubMed: 
27974643] 
[63]. Eisele P, Konstandin S, Szabo K, et al. Sodium MRI of T1 High Signal Intensity in the Dentate 
Nucleus due to Gadolinium Deposition in Multiple Sclerosis. J. Neuroimaging. 2017;27:372–
375. [PubMed: 28569398] 
[64]. Huhn K, Mennecke A, Linz P, et al. 23Na MRI reveals persistent sodium accumulation in 
tumefactive MS lesions. J. Neurol. Sci. 2017;379:163–166. [PubMed: 28716233] 
[65]. Fleysher L, Oesingmann N, Inglese M. B₀ inhomogeneity-insensitive triple-quantum-filtered 
sodium imaging using a 12-step phase-cycling scheme. NMR Biomed. 2010;23:1191–1198. 
[PubMed: 20677213] 
[66]. Fleysher L, Oesingmann N, Brown R, et al. Noninvasive quantification of intracellular sodium in 
human brain using ultrahigh-field MRI. NMR Biomed. 2013;26:9–19. [PubMed: 22714793] 
[67]. Petracca M, Vancea RO, Fleysher L, et al. Brain intra- and extracellular sodium concentration in 
multiple sclerosis : a 7 T MRI study. Brain. 2016;1–12. [PubMed: 27144254] ** Characterization 
of intra- and extracellular sodium concentration in multiple sclerosis
[68]. Nikić I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental 
autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 2011 [;17:495–499. [PubMed: 
21441916] 
[69]. Zhang B, Seifert A, Kim J, et al. 7 Tesla 22-channel wrap-around coil array for cervical spinal 
cord and brainstem imaging. MRM. 2017;78:1623–1634. [PubMed: 27859558] 
Inglese et al. Page 14
Expert Rev Neurother. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7.0 Key issues
• MS diagnosis is based on the presence of the two criteria of dissemination in 
space and in time coupled with the exclusion of alternative diagnoses that 
could offer a better explanation for the patient’s clinical presentation in 
patients who present symptoms consistent with a CNS inflammatory 
demyelinating disease.
• The main advantages of 7T MRI are the increased SNR and CNR that allow 
higher spatial resolution of fined anatomical and pathological details within 
reasonable acquisition times. The gain in SNR and CNR, however, occurs at 
the expense of increased radiofrequency (B1) and static field (B0) 
inhomogeneity which result in a variation of intensity across the image and 
distortions at structural boundaries that, in turn, can limit the interpretation of 
findings.
• 7T MRI provides higher sensitivity in WM and GM lesion detection 
compared to lower MRI fields. However, the gain is less than expected, 
especially with regard to GM lesions. Ongoing MRI sequence and RF coil 
development and optimization will hopefully overcome the limitations that 
prevent an optimal lesion detection at 7T.
• The central vein sign (CVS) has recently been proposed as a novel MRI 
biomarker to improve the accuracy and speed of MS diagnosis. Evidence 
indicates that the presence of the CVS in individual lesions can accurately 
differentiate MS from other diseases that mimic this condition. However, 
further studies are needed to establish the predictive value of the CVS for the 
development of clinical MS in patients with suspected demyelinating disease.
• Single quantum (SQ) 23Na MRI is an imaging technique that exploits the 
magnetic resonance properties of 23Na atomic nuclei. By combining SQ and 
triple-quantum filtered 23Na MRI at 7T is possible to quantify intra- and 
extracellular 23Na concentration. Preliminary findings suggest that the intra-
cellular 23Na increase in MS patients compared might indicate axonal 
dysfunction, offering insights in axonal metabolism before the generation of 
irreversible, axonal damage.
• Continued technical development of new signal transmission and readout 
methods is needed to overcome the limitations of performing 7T imaging in 
vivo. Additional clinical studies are needed to demonstrate the value of 7T for 
disease diagnosis, prognosis, treatment, and management.
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Figure 1. 
White matter lesionn detection at 3T and 7T. 3T and 7T axial images obtained for a patient 
with multiple slcerosis. White matter demyelinating lesions are visualized in greater detail in 
the 7T T2-weighted (first column) and T1-weighted image (second column). Image 
resolution: 3T T2-weighted=0.5×0.5×3 mm3,T1-weighted= 0.8×0.8×0.8 mm3; 7T T2-
weighted=0.7×0.7×0.7 mm3, T1-weighted=0.7×0.7×0.7 mm3.
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Figure 2. 
Perivenous distribution of multiple sclerosis lesions. 3 T FLAIR* (combined T2*-weighted 
MRI and FLAIR) images from four individuals with a variety of neurological conditions. In 
the patients with relapsing–remitting or primary progressive multiple sclerosis (MS), a 
central vessel is visible in most hyperintense lesions (arrows in magnified boxes). On the 
other hand, a central vein is absent from most of the lesions (arrowheads in magnified boxes) 
in the patient with migraine and the patient with ischaemic small vessel disease. Reproduced 
from Sati et al. [21] by permission of Nature Publishing Group (work is licensed under a 
Creative Commons Attribution 4.0 International License).
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Figure 3. 
7T axial images obtained for a patient with multiple slcerosis. Cortical lesion (arrow) is 
visualized on T1-weigthed sequence (A), T2-weighted sequence (B) and T2*-weighted 
sequence (C).
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Figure 4. 
A sagittal GRE image of the cervical spinal cord at 0.78 × 0.78 x 3 mm3 resolution (a) 
shows the positions of seven axial high-resolution (0.3 × 0.3 × 3 mm3) multi-echo image 
slices at vertebral levels C1 through C7 (b–h) where grey and white matter are clearly 
discernible. Images are courtesy of Dr. Junqian Xu, Ichan School of Medicine at Mount 
Sinai. Reproduced from Zhang et al. [66] by permission of John Wiley & Sons, Ltd.
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Figure 5. 
23Na group maps. Mean to total sodium concentration (TSC), (intracellular sodium 
concentration) ISC and (intra- cellular sodium volume fraction) ISVF maps for patients with 
multiple sclerosis (respectively, A, C and E) and controls (respectively, B, D and F). In both 
groups, TSC appears higher while ISC and ISVF are lower in grey matter than in white 
matter. As intracellular molar content and cell volume are equal to zero in extracellular 
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tissue, ISVF and ISC measurements in CSF are meaningless. Reproduced by Petracca et al. 
[67] by permission of Oxford University Press.
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